Find in Library

AIM: To investigate the clinical effect of vitrectomy combined with intravitreal injection of Conbercept for polypoidal choroidal vasculopathy(PCV)associated with vitreous hemorrhage. <p>METHODS: The clinical data of 59 patients(59 eyes)underwent vitrectomy in a hospital from May 2013 to August 2016 were retrospectively analyzed. Among them, 21 cases treated with vitrectomy were set as the control group; 38 cases treated with vitrectomy combined with intravitreal injection of conbercept were set up as the observation group. The efficacy and safety of the two groups were observed. <p>RESULTS: After the 12-month follow-up, the fundus examination of the observation group revealed that the deep, superficial retina hemorrhage and exudation of 38 patients were completely absorbed, and B-ultrasound showed that all patients with subretinal hemorrhage were also completely absorbed. However, B-ultrasound showed that subretinal hemorrhage and exudation still existed in 18 patients with varying degrees. The total BCVA changes before and after treatment in the two groups were statistically significant(<i>P</i><0.01). After 1, 3, 6 and 12mo of treatment, the BCVA in the observation group was all significantly better than that in the control group, and the statistical difference between the groups was significant(<i>P</i><0.05). After treatment, the changes of central retinal thickness(CRT)in the two groups were statistically different(<i>P</i><0.01). After 1wk, 1, 3, 6 and 12mo of treatment, the CRT in the observation group was all significantly lower than that in the control group, and the statistical difference between the groups was significant(<i>P</i><0.05). After 1wk of intravitreal Conbercept injection in observation group, the neovascularization of anterior chamber and iris of 37 cases completely subsided, only one case had a small residual neovascularization, the regression rate was 97%. After 1wk of vitrectomy in control group, the neovascularization of 16 cases subsided obviously with a regression rate of 76%. There was significant difference between groups(<i>χ</i>²=35.680, <i>P</i><0.001). No serious complications were observed in the two groups during follow-up, and there was no significant difference in the incidence of adverse reactions between the two groups(<i>P</i>>0.05). <p>CONCLUSION: Vitrectomy combined with intravitreal injection of conbercept is an effective and safe way for PCV associated with vitreous hemorrhage.